Universal influenza A vaccine: optimization of M2-based constructs. (Q49115229)

18 February 2018

title

Universal influenza A vaccine: optimization of M2-based constructs. (English)

1 reference

18 February 2018

1 reference

8

Walter Fiers

1 reference

18 February 2018

author name string

Marina De Filette

1

1 reference

18 February 2018

Willy Min Jou

2

1 reference

18 February 2018

Ashley Birkett

3

1 reference

18 February 2018

Katie Lyons

4

1 reference

18 February 2018

Brian Schultz

5

1 reference

18 February 2018

Anne Tonkyro

6

1 reference

18 February 2018

Stephanie Resch

7

1 reference

18 February 2018

language of work or name

English

0 references

publication date

1 June 2005

1 reference

18 February 2018

published in

Virology

1 reference

18 February 2018

volume

337

1 reference

18 February 2018

page(s)

149-161

1 reference

18 February 2018

issue

1

1 reference

18 February 2018

Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

Antibody response to the M2 protein of influenza A virus expressed in insect cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

Soluble recombinant influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

A "universal" human influenza A vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

Modified M2 proteins produce heterotypic immunity against influenza A virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

The annual production cycle for influenza vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

Updating the Accounts: Global Mortality of the 1918-1920 "Spanish" Influenza Pandemic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

Native display of complete foreign protein domains on the surface of hepatitis B virus capsids.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

Sequences of mRNAs derived from genome RNA segment 7 of influenza virus: colinear and interrupted mRNAs code for overlapping proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

Nasal-associated lymphoid tissue is a site of long-term virus-specific antibody production following respiratory virus infection of mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

B cell responses in gastric antrum and duodenum following oral inactivated Helicobacter pylori whole cell (HWC) vaccine and LT(R192G) in H pylori seronegative individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

The core antigen of hepatitis B virus as a carrier for immunogenic peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

A universal influenza A vaccine based on the extracellular domain of the M2 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

Infectious diseases. WHO ramps up bird flu vaccine efforts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

Human infection with influenza H9N2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

Taking toll: lipid A mimetics as adjuvants and immunomodulators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

Influenza virus M2 protein has ion channel activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

Influenza vaccines: a review and rationale for use in developed and underdeveloped countries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

HBV core particles as a carrier for B cell/T cell epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

Antibody-forming cells in the nasal-associated lymphoid tissue during primary influenza virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

Hepatitis core antigen produced in Escherichia coli: subunit composition, conformational analysis, and in vitro capsid assembly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

The crystal structure of the human hepatitis B virus capsid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

inferred from DOI database lookup

7 January 2021

based on heuristic

Antigenic determinants and functional domains in core antigen and e antigen from hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.004

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIROL.2005.04.004

1 reference

18 February 2018

PubMed ID

15914228

1 reference

18 February 2018